Literature DB >> 16087789

Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation.

Keisuke Ishizawa1, Yuki Izawa, Hiroyuki Ito, Chieko Miki, Kayoko Miyata, Yoshiko Fujita, Yasuhisa Kanematsu, Koichiro Tsuchiya, Toshiaki Tamaki, Akira Nishiyama, Masanori Yoshizumi.   

Abstract

The nongenomic effects of aldosterone have been implicated in the pathogenesis of various cardiovascular diseases. Aldosterone-induced nongenomic effects are attributable in part to the activation of extracellular signal-regulated kinase 1/2 (ERK1/2), a classical mitogen-activated protein (MAP) kinase. Big MAP kinase 1 (BMK1), a newly identified MAP kinase, has been shown to be involved in cell proliferation, differentiation, and survival. We examined whether aldosterone stimulates BMK1-mediated proliferation of cultured rat aortic smooth muscle cells (RASMCs). Mineralocorticoid receptor (MR) expression and localization were evaluated by Western blotting analysis and fluorolabeling methods. ERK1/2 and BMK1 activities were measured by Western blotting analysis with the respective phosphospecific antibodies. Cell proliferation was determined by Alamar Blue colorimetric assay. Aldosterone (0.1 to 100 nmol/L) dose-dependently activated BMK1 in RASMCs, with a peak at 30 minutes. To clarify whether aldosterone-induced BMK1 activation is an MR-mediated phenomenon, we examined the effect of eplerenone, a selective MR antagonist, on aldosterone-induced BMK1 activation. Eplerenone (0.1 to 10 micromol/L) dose-dependently inhibited aldosterone-induced BMK1 activation in RASMCs. Aldosterone also stimulated RASMC proliferation, which was inhibited by eplerenone. Aldosterone-mediated phenomena were concluded to be attributable to a nongenomic effect because cycloheximide failed to inhibit aldosterone-induced BMK1 activation. Transfection of dominant-negative MAP kinase/ERK kinase 5 (MEK5), which is an upstream regulator of BMK1, partially inhibited aldosterone-induced RASMC proliferation, which was almost completely inhibited by MEK inhibitor PD98059. In addition to the classical steroid activity, rapid nongenomic effects induced by aldosterone may represent an alternative etiology for vascular diseases such as hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087789     DOI: 10.1161/01.HYP.0000172622.51973.f5

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.

Authors:  Yasuhiro Nakamura; Saya Suzuki; Takashi Suzuki; Katsuhiko Ono; Ikumi Miura; Fumitoshi Satoh; Takuya Moriya; Haruo Saito; Shogo Yamada; Sadayoshi Ito; Hironobu Sasano
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

2.  Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.

Authors:  Yongji Yan; Chao Wang; Yiqin Lu; Huijie Gong; Zhun Wu; Xin Ma; Hongzhao Li; Baojun Wang; Xu Zhang
Journal:  J Physiol Biochem       Date:  2017-11-21       Impact factor: 4.158

3.  Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects.

Authors:  Takumi Sakurada; Keisuke Ishizawa; Masaki Imanishi; Yuki Izawa-Ishizawa; Shoko Fujii; Erika Tominaga; Teppei Tsuneishi; Yuya Horinouchi; Yoshitaka Kihira; Yasumasa Ikeda; Shuhei Tomita; Ken-ichi Aihara; Kazuo Minakuchi; Koichiro Tsuchiya; Toshiaki Tamaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-14       Impact factor: 3.000

4.  Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors.

Authors:  Dafina Pruthi; Amy McCurley; Mark Aronovitz; Carol Galayda; S Ananth Karumanchi; Iris Z Jaffe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-12-05       Impact factor: 8.311

5.  Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats.

Authors:  Paulo W Pires; Jonathon L McClain; Sebastian F Hayoz; Anne M Dorrance
Journal:  Microcirculation       Date:  2018-06-07       Impact factor: 2.628

Review 6.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

7.  Aldosterone activates NF-kappaB in the collecting duct.

Authors:  Valérie Leroy; Sophie De Seigneux; Victor Agassiz; Udo Hasler; Marie-Edith Rafestin-Oblin; Manlio Vinciguerra; Pierre-Yves Martin; Eric Féraille
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

Review 8.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

Review 9.  New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone.

Authors:  Catherine A Lemarié; Pierre Paradis; Ernesto L Schiffrin
Journal:  J Mol Med (Berl)       Date:  2008-03-27       Impact factor: 4.599

10.  A new drug delivery system targeting ileal epithelial cells induced electrogenic sodium absorption: possible promotion of intestinal adaptation.

Authors:  Sho Haneda; Kouhei Fukushima; Yuji Funayama; Chikashi Shibata; Ken-Ichi Takahashi; Yasuhiko Tabata; Iwao Sasaki
Journal:  J Gastrointest Surg       Date:  2007-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.